Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. The most frequent AE in table 1, are similar to AEs reported for both rigosertib and AZA as monotherapies, & the GU toxicities were mitigated using specific management guidelines. Myelodysplastic Syndromes – Clinical Studies: Poster III Abstract: 4249 Date:Monday, December 9, 2019 Presentation Time:6:00 PM - 8:00 PM Location:Hall B (Orange County Convention Center) Presenter:Anna Jonasova, MD, General University Hospital in Prague, 1st Internal Clinic - Clinic of Hematology, Prague, Czech Republic Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib 4. Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300.Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.
at the American Society of Hematology (ASH) 2019 Annual Meeting TOKYO, Japan, December 10, 2019 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that its U.S. licensor for Rigosertib, Onconova Therapeutics, Inc., (Headquarters: Newtown, PA, “Onconova”) announced on December 9, 2019 (EST) that Onconova Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition PDF Version Oral presentation will feature efficacy and safety data from Expanded Phase 2 Trial of oral rigosertib in combination with azacitidine
Myelodysplastic Syndromes – Basic and Translational Studies: Poster III Abstract: 4231 Date:Monday, December 9, 2019 Session Time:6:00 PM – 8:00 PM Location:Hall B (Orange County Convention Center) Presenter:Richa Rai, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NYOnconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company discovering and developing novel small molecule drug candidates to treat cancer, with a focus on Myelodysplastic Syndromes (MDS). Oral rigosertib was administered on D1-D21 of a 28D cycle. Search for other works by this author on:
Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition Onconova Therapeutics, Inc. November 7, 2019 GMT -- Oral presentation will feature efficacy and safety data from Expanded Phase 2 Trial of oral rigosertib … Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. We report updated results from a Phase II study in a subset of patients receiving oral rigosertib in combination with standard dose AZA as first line therapy for HR MDS.In the Phase II study 09-08, a total of 39 treatment-naïve HR MDS/RAEB-t patients received oral rigosertib in combination with standard dose AZA. AZA monotherapy has demonstrated improvement in OS in HR MDS, clinically meaningful and durable responses continue to be limited to a subset of patients (Silverman 2006). In total 20 pts were transfusion-dependent at study entry. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements.
Parenteral AZA 75mg/m2/day was administered for 7days from D8.
Oral rigosertib in combination with AZA was well tolerated and has now been administered in repetitive cycles for more than two years. Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome Session Name:636. 10 AEs led to D/C: urinary tract pain (2), and 1 each for urinary retention, hematuria, hydronephrosis, osteolysis, cerebral haemorrhage, WBC count decreased, neutrophil count decreased, & abd pain. Search for other works by this author on:
Rigosertib is attractive combination partner for AZA because of the oral formulation, non-overlapping toxicity, mechanism of action and synergy.
This dosage form may also support combination therapy modalities. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements.
Search for other works by this author on: This dosage form may also support combination therapy modalities. Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Session Name:637.
In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them.